Dr. Silviu Itescu, CEO of the biotech company Mesoblast (MESO), joins Market On Close. The company is developing therapeutics using stem cells to target severe inflammatory conditions, including pediatric conditions. He discusses Mesoblast’s recent FDA approval for a cell therapy that is the first of its type, and its potential uses in bone marrow transplant patients.